Amarin Corp Plc (AMRN)

[VuBru]

In event of failed primary outcome, what happens depends on whether V is found to reduce MACE in specific subgroups (e.g., diabetics). If so, given that it is already an approved drug and the first amendment win, they could legitimately promote it for use in a larger population than covered by the current indication. For example, diabetics with moderately elevated TGs. This would increase revenue and PPS (eventually) even in context of a formally failed trial. I am sure the company has planned for this contingency.